Novartis' pelacarsen misses its cardiovascular endpoint, erasing CHF4.9 billion and raising the bar for every Lp(a) rival

Novartis' pelacarsen missed the primary endpoint of the double-blind, placebo-controlled phase III Lp(a)HORIZON study, failing to reduce a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and urgent coronary revascularization against placebo . The trial enrolled 8,323 patients. Roughly CHF4.9 billion evaporated from the company's market value on the result.

The detail that matters for everyone else in the field is what pelacarsen did succeed at. It lowered Lp(a). It simply did not translate that into fewer cardiovascular events, which puts the question on the mechanism rather than on this one molecule. That is why the damage spread: AMGN fell about 5% in after-hours trading, and Ionis Pharmaceuticals, pelacarsen's development partner, also declined. Broader coverage of the readout names Amgen's olpasiran, Eli Lilly's lepodisiran and Silence Therapeutics' zerlasiran as the late-stage programs whose risk profile rises on this data, though the specific articles in this cluster name only Amgen. Novartis' Chief Medical Officer Shreeram Aradhye said these were not the results the company hoped for while noting the data advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes.

Two figures circulating around this story measure different things and should not be blended. The CHF4.9 billion is market value that actually disappeared. The separate $6 billion figure in some coverage is the top of an analyst range of $3 billion to $6 billion in projected peak annual sales, a discounted future revenue estimate revised to zero, not cash or capitalisation lost. Novartis' own share move is also reported inconsistently across the day, at 1.9% in one headline and more than 3%, 3.3%, and as much as 3.9% in early Zurich trading elsewhere; these are plausibly the same session read at different hours, but no single source reconciles them, so treat the precise decline as unsettled. The ADR was cited at $159.99.

What to watch is the next readout. With pelacarsen out, attention pivots to Novartis' del-desiran as the must-win pipeline event, and to Amgen's olpasiran phase 3, estimated for completion in December 2026, which is now the cleanest test of whether the Lp(a) hypothesis survives at all. A second failure on the same mechanism would reprice the whole class rather than one company.

Related Stocks

• NVS
• AMGN